Company: FTII
Filing Date: 2025-07-17
Form Type: PRE 14A
Source: 0001641172-25-020051
Chunk: 52

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-07-17
Form: PRE 14A
Chunk 52
---
 acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. On February 18, 2022, we consummated our initial public offering of 11,500,000 units at $10.00 per unit, generating gross proceeds of $115,000,000, including full exercise of the underwriters’ option to purchase additional units. Each unit consists of one share of common stock and one redeemable warrant, with each warrant entitling the holder thereof to purchase one share of common stock at a price of $11.50 per share. Simultaneously with the consummation of our initial public offering, we consummated the private placement of 520,075 private units to FutureTech Partners II LLC (the “Sponsor”) at a price of $10.00 per private unit, generating gross proceeds of $5,200,750.

As announced before, FutureTech entered into that certain Merger Agreement with Longevity Biomedical Inc and other related parties on September 16, 2024. However, FutureTech’s charter provides that FutureTech has until August 18, 2025 to consummate a business combination. While we are using our best efforts to complete the Business Combination as soon as practicable, the Board believes that there will not be sufficient time before the Termination Date to complete the Business Combination. Accordingly, the Board believes that in order to be able to complete the Business Combination, we will need to obtain the Extension. Without the Extension, the Board believes that there is significant risk that we might not, despite our best efforts, be able to complete the Business Combination on or before August 18, 2025. If that were to occur, we would be precluded from completing a Business Combination and would be forced to liquidate even if our stockholders are otherwise in favor of consummating a Business Combination. The affirmative vote of the holders of at least sixty-five percent (65%) of all outstanding shares of common stock is required to extend FutureTech’s corporate existence, except in connection with, and effective upon consummation of, a business combination. Additionally, FutureTech’s IPO prospectus and charter provide for all public stockholders to have an opportunity to redeem their public shares in the case FutureTech’s corporate existence is extended as described above. Because FutureTech continues to believe that a business combination would be in the best interests of FutureTech’s stockholders, and because FutureTech will not be able to conclude a business